Apollo hospitals performs world-first Renal denervation therapy with Simplicity Spyral for a hypertensive patient with Ectopic kidney
Hypertension,
or high blood pressure, is a prevalent condition affecting nearly one-third of
individuals over 40 years old. Controlling blood pressure is crucial, as even a
modest 5mmHg reduction can decrease the risk of stroke by 34%, ischemic heart
disease by 21%, and mortality by 13%.
The
58-year-old patient had an ectopic left kidney located in the right iliac
fossa, supplied by two separate renal arteries – an extremely rare anatomical
variation. The innovative RDN therapy involved radiofrequency ablation of both
renal arteries, leading to a remarkable reduction in the patient's blood
pressure from over 160/100 mmHg to 130/80 mmHg within a day. He was discharged
the next day, requiring only two medications instead of the previous five.
Dr.
Refai Showkathali, Senior Consultant, Interventional Cardiology, Apollo
Hospitals Chennai, said, "We are happy to have successfully performed the
world's first Simplicity Spyral RDN therapy on a patient with an ectopic
kidney. This procedure offers new hope for patients with complex resistant
hypertension conditions. The patient's significant improvement demonstrates the
therapy's potential in managing obstinate cases of high blood pressure."
Medtronic
Global has confirmed this is the first-ever use of the FDA-approved Simplicity
Spyral RDN catheter in ectopic kidneys worldwide, out of approximately 20,000
procedures performed globally.
While
appropriate medication and lifestyle modifications are the frontline treatments
for hypertension, some patients may require additional interventions like RDN
for better blood pressure control. This breathtaking achievement showcases
Apollo Hospitals Chennai's leadership in interventional cardiology and its
commitment to pioneering medical advancements that improve
patient outcomes.
Comments
Post a Comment